Head and Neck Cancer - Pipeline Insight, 2024

This “Head and Neck Cancer - Pipeline Insight, 2024,”report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Head and Neck Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Head and Neck Cancer Understanding

Head and Neck Cancer: Overview

Head and neck cancer is a collective term that includes several different types of cancers. Cancers of the head and neck are categorized by the area in which they begin. This includes the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. The most common type of head and neck cancer is squamous cell carcinoma of the head and neck (HNSCCA). Most HNSCCA begins in the layer of flat cells (the epithelium) which line the structures of the upper aero digestive tract, including the mouth, throat, and voice box. HNSCCA accounts for about three to five percent of all cancers in the United States, where, in 2021, an estimated 54,000 people will be diagnosed with head and neck cancer and approximately 11,000 will die of the disease. Globally, there were an estimated 890,000 cases in 2018 along with 450,000 deaths.

The five-year survival rate of patients with head and neck cancer is about 60 percent. Environmental risk factors for head and neck cancers include tobacco use, heavy alcohol consumption, prolonged sun exposure, and certain viruses, including human papilloma virus (HPV) and Epstein-Barr virus (EBV). Treatment for head and neck cancer depends on individual factors, including the exact location of the tumor, stage of the tumor, and a person’s general health. These conventional treatments for head and neck cancer (surgery, radiation, and chemotherapy) may be used alone or in combination, depending on stage and location.

Head and neck cancer can be hard to diagnose because symptoms are often mild and can mimic less serious conditions like a cold or a persistent sore throat, frequent headaches. Hoarseness or voice changes pain while chewing or swallowing facial numbness or pain a lump in the throat, mouth or neck, swelling in jaw, neck or side of face (that may cause dentures to fit poorly).

The diagnosis and treatment plans includes physical examination, endoscopy, imaging tests like CT scans, MRI, PET Scans and biopsy .There are three main treatments that are widely used to cure cancer that are surgery, radiation therapy and chemotherapy and targeted therapy and immunotherapy drugs activate (or boost) the immune system to identify and destroy cancer cells more effectively. Pembrolizumab (Keytruda®) and nivolumab (Opdivo®) are two FDA-approved immunotherapy drugs used to treat certain head and neck cancers.

Head and Neck Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Head and Neck Cancer pipeline landscape is provided which includes the disease overview and Head and Neck Cancer treatment guidelines. The assessment part of the report embraces, in depth Head and Neck Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Head and Neck Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Head and Neck Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Head and Neck Cancer.

Head and Neck Cancer Emerging Drugs Chapters

This segment of the Head and Neck Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Head and Neck Cancer Emerging Drugs

Xevinapant : MerckXevinapant is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins). IAP inhibitors restore sensitivity to apoptosis in cancer cells and thereby deprive them of one of their major resistance mechanisms. The drug is under an exclusive license agreement with Merck. Xevinapant received FDA granted Breakthrough Therapy Designation. Currently it is in Phase III stage of clinical trial evaluation to treat Head and Neck Cancer.

Durvalumab : AstraZenecaDurvalumab (MEDI4736) is an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumors avoid detection by the immune system. The drug blocks these signals, countering the tumor’s immune-evading tactics. MEDI4736 is being developed, alongside other immunotherapies, to empower the patient’s immune system and attack the cancer. Currently being evaluated in the Phase III studies for the treatment of head and neck cancer.

Tipifarnib : Kura OncologyTipifarnib is an oral, small molecule drug candidate and highly selective inhibitor of farnesyltransferase. The drug is in Phase II stage of clinical trials for the treatment of head and neck cancer.

Iopofosine: Cellectar BiosciencesLopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The drug is being developed in collaboration with University of Wisconsin-Madison. The drug is in Phase I stage of clinical trials for the treatment of head and neck cancer.

Head and Neck Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Head and Neck Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Head and Neck Cancer

• There are approx. 100+ key companies which are developing the therapies for Head and Neck Cancer. The companies which have their Head and Neck Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck

Phases

This report covers around 120+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Head and Neck Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Head and Neck Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Head and Neck Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Head and Neck Cancer drugs.

Head and Neck Cancer Report Insights

• Head and Neck Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Head and Neck Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Head and Neck Cancer drugs?
• How many Head and Neck Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Head and Neck Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Head and Neck Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Head and Neck Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Debiopharm/Merck
• AstraZeneca/MedImmune
• Eisai Co Ltd/Merck & Co
• Kura Oncology
• Cellectar Biosciences
• Galera Therapeutics, Inc.
• BioMimetix JV, LLC
• Bristol-Myers Squibb
• QBiotics Group Limited
• Alentis Therapeutics AG
• Coordination Pharmaceuticals, Inc.
• Bristol-Myers Squibb
• Genmab
• Merck Sharp & Dohme LLC
• Immunovative Therapies, Ltd.
• TyrNovo Ltd
• BioNTech SE
• Aveta Biomics, Inc.
• Pfizer
• Cue Biopharma

Key Products

• Xevinapant
• Durvalumab
• Lenvatinib
• Tipifarnib
• Lopofosine
• GC4419
• BMX-001
• Paclitaxel
• Tigilanol Tiglate
• ALE.C04
• RiMO-301
• Nivolumab
• Zalutumumab
• Pembrolizumab
• AlloVax
• NT219
• BNT113
• APG-157
• Palbociclib
• CUE-101

This product will be delivered within 1-3 business days.